CompletedNCT05723068
Burden of Hepatitis D Virus (HDV) Infection in Italy
Studying Hepatitis delta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Turin, Italy
- Principal Investigator
- Mario Rizzetto, MD, M.DUniversity of Turin, Italy
- Enrollment
- 515 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2024
Study locations (30)
- Università degli Studi di Bari Aldo Moro, Bari, Italy
- Gastroenterology Hepatology and Transplantation, ASST Bergamo, Bergamo, Italy
- Malattie Infettive, ASST Bergamo, Bergamo, Italy
- Dipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di Bologna, Bologna, Italy
- Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, Brescia, Italy
- UOC Malattie Infettive e Tropicali, A.O. S Anna e S Sebastiano, Caserta, Italy
- UOS Epatologia "G. Rodolico-San Marco", Catania, Italy
- UOC Medicina Interna Ospedaliera, Policlinico "Mater Domini", Catanzaro, Italy
- Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Foggia, Italy
- S.C. Malattie Infettive, E.O. Ospedali Galliera, Genova, Italy
- UOC Malattie Infettive, Ospedale Paolo Borsellino di Marsala, Marsala, Italy
- A.O.U. Policlinico G. Martino di Messina, Università di Messina, Messina, Italy
- Dipartimento di Malattie Infettive e Centro Epatopatie, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- Dipartimento di Malattie Infettive, ASST Fatebenefratelli - Ospedale Luigi Sacco, Milan, Italy
- UOC Gastroenterologia e Epatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy
- +15 more locations on ClinicalTrials.gov
Collaborators
Gilead Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05723068 on ClinicalTrials.govOther trials for Hepatitis delta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07454837Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideMirum Pharmaceuticals, Inc.
- RECRUITINGNCT07491848Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+DResearch Center of Periodontal-Systemic Interactions
- RECRUITINGPHASE3NCT07298330A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT07317011"Referral Attivo" Delta, Dallo Screening Alla Presa in Carico.FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGNCT07429864Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With BulvertideFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT07200908A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)Mirum Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionVir Biotechnology, Inc.
- RECRUITINGPHASE1, PHASE2NCT07096193Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta VirusGilead Sciences